Zacks Investment Research upgraded shares of United Therapeutics Corporation (NASDAQ:UTHR) from a strong sell rating to a hold rating in a report released on Monday morning.
According to Zacks, “United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. Lately, the growth of its PAH drugs Orenitram, Tyvaso and Remodulin have slowed due to competition from Uptravi and Adcirca + Letairis combination therapy. Also, recently, the company announced that regulatory issues will delay the U.S. launch of RemoSynch. The company is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Though Orenitram sales growth was slow in 2016, management estimates the drug to have $1 billion peak revenue potential. Shares also underperformed the industry this year so far. Estimates have remained stable ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in the recent quarters.”
UTHR has been the subject of several other research reports. Jefferies Group LLC reiterated a sell rating and set a $105.00 price target on shares of United Therapeutics Corporation in a research report on Friday, July 14th. TheStreet cut shares of United Therapeutics Corporation from a b- rating to a c rating in a research report on Friday, September 29th. UBS AG reiterated a sell rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. ValuEngine cut shares of United Therapeutics Corporation from a strong-buy rating to a buy rating in a research report on Friday, July 28th. Finally, BidaskClub upgraded shares of United Therapeutics Corporation from a sell rating to a hold rating in a research report on Friday, June 16th. Five investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company. United Therapeutics Corporation has an average rating of Hold and an average target price of $132.09.
United Therapeutics Corporation (NASDAQ UTHR) opened at 120.27 on Monday. The company has a market capitalization of $5.22 billion, a PE ratio of 13.95 and a beta of 1.49. United Therapeutics Corporation has a 12-month low of $110.90 and a 12-month high of $169.89. The stock has a 50 day moving average of $123.41 and a 200 day moving average of $126.40.
United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing the consensus estimate of $3.61 by ($4.86). United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company had revenue of $444.60 million during the quarter, compared to analyst estimates of $391.53 million. During the same quarter in the previous year, the business posted $4.42 EPS. The company’s revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts predict that United Therapeutics Corporation will post $10.60 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “United Therapeutics Corporation (UTHR) Raised to “Hold” at Zacks Investment Research” was published by BBNS and is the property of of BBNS. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://baseballnewssource.com/markets/united-therapeutics-corporation-uthr-raised-to-hold-at-zacks-investment-research/1704107.html.
In other United Therapeutics Corporation news, Director Christopher Causey sold 580 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $134.48, for a total value of $77,998.40. Following the transaction, the director now owns 3,295 shares of the company’s stock, valued at $443,111.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 1,247 shares of United Therapeutics Corporation stock in a transaction that occurred on Thursday, July 27th. The shares were sold at an average price of $126.40, for a total transaction of $157,620.80. Following the completion of the transaction, the chief executive officer now directly owns 2,316 shares in the company, valued at approximately $292,742.40. The disclosure for this sale can be found here. Insiders have sold a total of 17,060 shares of company stock worth $2,160,854 in the last three months. 7.80% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. JPMorgan Chase & Co. lifted its stake in United Therapeutics Corporation by 1.8% in the first quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock valued at $16,583,000 after buying an additional 2,223 shares in the last quarter. Stifel Financial Corp lifted its stake in United Therapeutics Corporation by 49.1% in the first quarter. Stifel Financial Corp now owns 3,073 shares of the biotechnology company’s stock valued at $412,000 after buying an additional 1,012 shares in the last quarter. Clinton Group Inc. bought a new position in United Therapeutics Corporation in the first quarter valued at approximately $363,000. Victory Capital Management Inc. lifted its stake in United Therapeutics Corporation by 8.7% in the first quarter. Victory Capital Management Inc. now owns 5,416 shares of the biotechnology company’s stock valued at $733,000 after buying an additional 432 shares in the last quarter. Finally, Neuberger Berman Group LLC lifted its stake in United Therapeutics Corporation by 22.8% in the first quarter. Neuberger Berman Group LLC now owns 4,923 shares of the biotechnology company’s stock valued at $666,000 after buying an additional 915 shares in the last quarter.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with our FREE daily email newsletter.